Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recarbrio PK and Safety in CF Pulmonary Exacerbations
NCT05561764Phase 4Terminated
- Sponsor
- Hartford Hospital
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imipenem + cilastatin + relebactam in cystic fibrosis (CF) and bacterial pneumonia, sponsored by Hartford Hospital. Primary endpoints: Imipenem Clearance at 6 hours, Relebactam Clearance at 6 hours and 2 more. Started Jan 2023; status: terminated.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
cystic fibrosis (CF)bacterial pneumonia
Beyond the preview
Go deeper on NCT05561764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561764.